<DOC>
	<DOCNO>NCT02477618</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled trial , design evaluate efficacy safety SAGE-547 administer continuous intravenous infusion subject Super-Refractory Status Epilepticus ( SRSE ) .</brief_summary>
	<brief_title>A Study With SAGE-547 Super-Refractory Status Epilepticus</brief_title>
	<detailed_description />
	<mesh_term>Status Epilepticus</mesh_term>
	<criteria>Subjects two ( 2 ) year age old Subjects : Failed respond administration least one firstline agent ( e.g. , benzodiazepine emergent initial AED treatment ) , accord institution standard care , ; Failed respond least one secondline agent ( e.g. , phenytoin , fosphenytoin , valproate , phenobarbital , levetiracetam urgent control AED ) , accord institution standard care , ; Not previously administer thirdline agent admit intensive care unit intent administer least one thirdline agent least 24 hour ; previously fail zero , one wean attempt thirdline agent continuous intravenous infusion one thirdline agent EEG burst seizure suppression pattern ; previously fail one wean attempt thirdline agent either continuous intravenous infusion least one thirdline agent continuous intravenous infusion one thirdline agent EEG burst seizure suppression pattern Subjects SRSE due anoxic/hypoxic encephalopathy highly malignant/ malignant EEG feature Children ( subject age less 17 year ) encephalopathy due rapidly progress underlie neurological disorder Subjects follow : 1. GFR low enough warrant dialysis whatever reason , dialysis plan noncontinuous dialysis plan ( would adequately remove CaptisolÂ® ) ; 2. severe cardiogenic vasodilatory shock require two pressor related thirdline agent use ; 3. fulminant hepatic failure ; 4. reasonable expectation recovery ( instance , likely outcome persistent vegetative state ) lifeexpectancy , experience investigator , less 30 day . Subjects administer three thirdline agent concomitantly qualify wean complete per protocol</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>